Posted by Michael Wonder on 16 Jan 2024
Nurix Therapeutics receives US FDA fast track designation for NX-5948 for the treatment of relapsed or refractory CLL and SLL
16 January 2024 - Fast track designation follows positive Phase 1 data presented at the American Society of Hematology that supports strategy to broadly develop NX-5948 in CLL and other non-Hodgkin lymphoma indications.
Nurix Therapeutics today announced that the US FDA has granted fast track designation for NX-5948, a highly selective degrader of Bruton’s tyrosine kinase, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma after at least two lines of therapy, including a Bruton's tyrosine kinase inhibitor and a B-cell lymphoma 2 inhibitor.
